New York, New York — November 16, 2025 — Leads & Copy — Obagi Medical, a part of Waldencast plc (NASDAQ: WALD), has announced new data shared at the American Society for Dermatologic Surgery (ASDS) Annual Meeting in Chicago, Illinois, held November 13–16, 2025.
Dr. Sue Ellen Cox presented the data from a pivotal FDA study comparing two hyaluronic acid fillers for midface augmentation and the associated improvement in nasolabial folds appearance, with Obagi Hyaluronic Acid featured as a Top 10 Abstract.
Cox stated that the data highlights the compelling results of the Obagi® saypha® ChIQ™ pivotal study, demonstrating the product’s potential to provide high-level satisfaction for patients seeking long-lasting, natural-looking results.
The multicenter trial compared the effectiveness and safety of two hyaluronic acid fillers for midface volume restoration and nasolabial fold improvement, demonstrating non-inferiority of Obagi® saypha® ChIQ™ compared to Juvéderm Voluma® XC. The study also noted high patient satisfaction and robust safety across diverse skin types.
Interim data from the ongoing study of Obagi Nu-Cil® BioStim™ Scalp Serum highlights improvements in scalp health and hair appearance at three months.
Additionally, research introduced a novel framework for evaluating HA fillers, showcasing category-leading capabilities of the Obagi line of injectables.
Drew Fine, U.S. General Manager, Professional Channel, stated that Obagi Medical’s commitment to advancing dermatologic science and driving innovation is reflected in the data shared across its skincare and injectable portfolio at the ASDS meeting. Fine added that the selection of the Obagi® saypha® ChIQ™ abstract as one of the top 10 for oral presentation highlights the powerful data supporting the new Obagi injectable.
Nu-Cil® BioStim™ Scalp Serum utilizes proprietary technology powered by a blend of clinically proven actives, including biotin, amino acids, and peptides—alongside 18 essential nutrients, B vitamins, and phytoactives to promote scalp health, fortify hair follicles, and strengthen strands from the root.
Obagi® saypha® ChIQ™, developed by Croma-Pharma GmbH, utilizes proprietary MACRO Core Technology that creates a stable 3D HA matrix designed to provide natural-looking results with category-leading capabilities, including high HA content upon injection, consistent gel distribution, and a predictable injection force and swelling profile. Obagi Medical’s Obagi® saypha® MagIQ™ was recently FDA approved, while Obagi® saypha® ChIQ™ is currently under review for FDA approval.
More information about Obagi Medical is available on the brand’s website.
ICR
WaldencastIR@icrinc.com
ICR
WaldencastPR@icrinc.com
Source: Obagi Medical
